BNP Paribas Financial Markets Sells 88,191 Shares of Evogene Ltd. (NASDAQ:EVGN)

BNP Paribas Financial Markets cut its position in Evogene Ltd. (NASDAQ:EVGN) by 87.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 12,200 shares of the biotechnology company’s stock after selling 88,191 shares during the quarter. BNP Paribas Financial Markets’ holdings in Evogene were worth $37,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Investment Group LLC bought a new stake in Evogene during the third quarter valued at about $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Price Performance

Shares of Evogene stock opened at $1.29 on Friday. The company has a market cap of $6.92 million, a PE ratio of -0.29 and a beta of 1.36. The firm has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $3.68. Evogene Ltd. has a fifty-two week low of $1.20 and a fifty-two week high of $10.40.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. StockNews.com assumed coverage on Evogene in a research note on Friday. They issued a “sell” rating on the stock. Lake Street Capital dropped their price target on Evogene from $30.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, August 23rd.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.